在复发性/转移性状细胞头癌中,免疫治疗进展后的救生化疗
Sandra Llop1, Maria Plana1, Sara Tous2,3
1Department of Medical Oncology, Catalan Institute of Oncology (ICO), L'Hospitalet de Llobregat, Barcelona, Spain.
Frontiers in oncology
|December 10, 2024
概括
救援化疗 (SCT) 显示出在反复或转移的头角状细胞癌 (R/M HNSCC) 中显著的疗效,在抗PD-(L) 1治疗后. PD-L1状态是反应和生存的关键预测因素,指导个性化治疗策略.
科学领域:
- 在瘤学瘤学.
- 头部和部癌症 头部和部癌症
- 免疫治疗是一种免疫疗法.
背景情况:
- 反编程死亡 (联结体) 1 [PD-(L) 1] 剂已经改变了R/M HNSCC治疗.
- 在抗PD-(L) 1治疗后的救生化疗 (SCT) 在之前的研究中显示出有前途.
- 在这种情况下,在SCT后反应和生存的预测因素需要进一步阐明.
研究的目的:
- 为了评估SCT在R/M HNSCC患者在抗PD-(L) 1治疗后的结果.
- 在这个患者群体中确定反应和生存的预测因素.
主要方法:
- 对63名R/M HNSCC患者的回顾性队列分析,这些患者接受了SCT后抗PD-(L) 1治疗.
- 评估整体应答率 (ORR),无进展生存率 (PFS) 和整体生存率 (OS).
- 后勤和考克斯回归分析以确定结果预测因素.
主要成果:
- SCT的ORR为49%,在PD-L1阳性瘤 (71%对18%) 和含有 cetuximab的疗法 (68%对39%) 中显著更高.
- PD-L1状态是ORR,OS,PFS和PFS2-I (抗PD-L1治疗后进展的时间) 的唯一独立预测因素.
- 平均OS和PFS分别为9.3个月和4.1个月.
结论:
- PD-L1状态是R/M HNSCC患者SCT疗效的强有力的预测指标,这些患者在抗PD-L1药物中进展.
- 含有 cetuximab 的疗法可能会带来额外的益处.
- 基于PD-L1表达的治疗顺序和个性化策略至关重要.
相关概念视频
Tumor Immunotherapy
476
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
476
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
174
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
174
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K


